Given that the chronic conditions caused by high expression of DYRK1A, such as DS and AD, would require a long-term treatment with DYRK1A inhibitor drugs, it will be essential to evaluate the safety of these drugs given the emerging role of this kinase in cancer. The gene discussed is DYRK1A; the disease is Dravet syndrome.